Skinvisible files provisional patent for transdermal obesity drug delivery using Invisicare

SKINVISIBLE, INC.

Provisional patent filed for transdermal composition of CB-1 receptor antagonists and/or GLP-1 receptor agonists.
Uses proprietary Invisicare technology; studies show up to 10x increase in transdermal delivery effectiveness.
Aims to offer needle-free alternative to injections for obesity drugs; potential to improve compliance.
Global obesity drug market projected to exceed $30B by 2027.
Company actively seeking strategic partnerships for development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.